Randomized trials demonstrated improved clinical outcomes when therapeutic-dose heparin is administered to non-critically ill patients hospitalized for coronavirus disease 2019 (COVID-19) and this is now recommended in practice guidelines. In contrast, clinical trials showed that therapeutic-dose heparin is not beneficial, and potentially harmful, when initiated in critically ill patients. Therefore, it is uncertain whether therapeutic-dose heparin should continue or be dose reduced when a patient transitions from non-critically ill to critically ill...
- Drug therapy
- Patient outcomes